Evidence map›Paper›PMID 31487003›Full record

ArticleMolecular neurobiology2020

Downregulation of 14-3-3 Proteins in Alzheimer's Disease.

Qiang Gu, Elvis Cuevas, James Raymick, Jyotshna Kanungo, Sumit Sarkar

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Key Proteins in Rat Cerebral Cortex: Application ofMolecules (Basel, Switzerland) · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Qiang GuDivision of Neurotoxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, HFT-132, 3900 NCTR Road, Jefferson, AR, 72079, USA. qiang.gu@fda.hhs.gov.
Elvis CuevasDivision of Neurotoxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, HFT-132, 3900 NCTR Road, Jefferson, AR, 72079, USA.
James RaymickDivision of Neurotoxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, HFT-132, 3900 NCTR Road, Jefferson, AR, 72079, USA.
Jyotshna KanungoDivision of Neurotoxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, HFT-132, 3900 NCTR Road, Jefferson, AR, 72079, USA.
Sumit SarkarDivision of Neurotoxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, HFT-132, 3900 NCTR Road, Jefferson, AR, 72079, USA.
United States Food and Drug Administration · USNational Center for Toxicological Research · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the most abundant proteins expressed in the brain, 14-3-3 comprises about 1% of the brain's total soluble proteins. The 14-3-3 isoforms bind to specific phosphoserine- and phosphothreonine-containing motifs found on a variety of signaling proteins (kinases and transcription factors, among others) to regulate a wide array of cellular processes including cell cycling, apoptosis, and autophagy. Previously, we described the expression of different 14-3-3 isoforms in the rat frontal cortex and reported their downregulation in a rodent model of neurodegeneration. To further investigate possible roles of 14-3-3 proteins in neurodegeneration, the present study examined different 14-3-3 isoforms in the frontal cortex of postmortem Alzheimer's disease (AD) patients and control subjects. Among the different 14-3-3 isoforms in the human frontal cortex, the relative abundance of expression is in the following order: 14-3-3-eta > tau > sigma > gamma > epsilon > zeta/delta > beta/alpha. These relative abundance levels of different 14-3-3 isoforms in human frontal cortex closely resemble those in rat frontal cortex, suggesting a conserved expression pattern of different 14-3-3 isoforms in mammalian species. In the AD samples, there was a significant decrease in total 14-3-3 levels and the 14-3-3-eta and 14-3-3-gamma isoforms, while no significant difference in the expression level of other 14-3-3 isoforms between AD and control brains was detected. Together, these results demonstrate an abundance of several 14-3-3 isoforms in the frontal cortex and that a downregulation of total 14-3-3 protein levels and specific 14-3-3 isoforms is associated with neurodegeneration. Given the known function of 14-3-3 proteins as inhibitors of apoptosis, the present results suggest that 14-3-3 proteins may play an important role in neurodegeneration and deserve further investigations into AD and other neurodegenerative disorders.

Indexed as

14-3-3 ProteinsAgedAged, 80 and overAlzheimer DiseaseBrainDown-RegulationFemaleFrontal LobeHumansMaleMiddle AgedProtein Isoformstau Proteins14-3-3 ProteinsProtein Isoformstau Proteins14-3-3 proteinsAlzheimer’s diseaseApoptosisFrontal cortexNeurodegeneration

Identifiers

PMID31487003
OpenAlexW2972040783

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.